Hanmi signs record $2.3b obesity drug deal with Genentech
Kort samengevat
Hanmi Pharmaceutical said Monday it has inked an exclusive licensing agreement with Genentech for its obesity drug candidate HM17321 in a deal that could be wor
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij The Korea Herald.
Lees het volledige bericht ↗